SERTRALINE FOR THE PREVENTION OF RELAPSE IN DETOXICATED ALCOHOL DEPENDENT PATIENTS WITH A COMORBID DEPRESSIVE DISORDER: A RANDOMIZED CONTROLLED TRIAL
|
|
- Primrose Stewart
- 5 years ago
- Views:
Transcription
1 Alcohol & Alcoholism Vol. 38, No. 6, pp , 2003 doi: /alcalc/agg124, available online at SERTRALINE FOR THE PREVENTION OF RELAPSE IN DETOXICATED ALCOHOL DEPENDENT PATIENTS WITH A COMORBID DEPRESSIVE DISORDER: A RANDOMIZED CONTROLLED TRIAL A. GUAL 1 *, M. BALCELLS 1, M. TORRES 1, M. MADRIGAL 2, T. DIEZ 2 and L. SERRANO 1 1 Unitat de Alcohologia de la Generalitat de Catalunya, Villaroel, Barcelona and 2 Pfizer SA, Parque Empresarial La Moraleja, Madrid, Spain (Received 20 February 2003; accepted 12 August 2003) Abstract Aims: We performed a double-blind, placebo-controlled randomized trial of sertraline in recently detoxified alcoholdependent patients with current depressive symptoms. The objectives of the study were to evaluate the efficacy of sertraline at achieving stable abstinence, at ameliorating depressive symptoms and at improving quality of life in these patients. Methods: The study included 83 patients, who received either sertraline ( mg/day) or placebo for 24 weeks. The primary outcome criteria were the rate of relapse into alcohol consumption and the rate of response on the Montgomery and Åsberg Depression Rating Scale (MADRS). Results: At the end of the treatment period, relapse rates were 23.1% in the placebo group and 31.8% in the sertraline group. Responder rates for depression were 38.5% for the placebo group and 44.2% for the sertraline group. There was no significant difference between treatment groups with either variable. However, when patients were stratified into severe (MADRS score 26) and moderate (MADRS score 26) depression at inclusion, a significant treatment benefit with sertraline was observed in the former group. Quality of life, determined by the SF-36, improved in both groups, with more benefit observed for the sertraline group on mental health items. Sertraline was well tolerated, and the incidence of adverse events was similar in the two treatment groups. Conclusions: The explanation for the overall good outcome in both treatment groups and for the inability to demonstrate a clear treatment effect may reside in the clinical features of the patients included. INTRODUCTION Comorbidity of depression and alcohol dependence is common (Regier et al., 1990; Kessler et al., 1994); major depressive episodes appear to be approximately twice as frequent in alcohol-dependent patients than they are in the general population. Comorbid depression is a negative prognostic factor for achieving stable abstinence in alcohol dependence (Rounsaville et al., 1987; O Sullivan et al., 1988; Driessen et al., 2001) whilst active alcohol dependence is a negative prognostic factor for remission of depressive symptoms (Mueller et al., 1994). In addition, comorbidity is associated with an increased risk of suicide (Murphy et al., 1992). For these reasons, identification and treatment of depressive symptoms is an important issue in the management of alcohol dependent patients. Understanding the origin and course of depression in alcohol-dependent patients has important implications for how it should be treated (O Sullivan, 1984; Thase et al., 2001). Several different hypotheses have been put forward to account for this increased comorbidity (Berner et al., 1986; Swendsen and Merikangas, 2000). First, it is possible that depression and alcohol dependence exist as distinct pathologies in individuals who are predisposed to them as a result of common aetiological factors. These could be either genetic susceptibility factors (Kendler et al., 1997), or priming events occurring early in life such as childhood trauma (Roy, 1996a). Second, alcohol dependence and depression may be causally linked. Depressive symptoms may appear as a consequence of chronic alcohol use in subjects who had no history of depression prior to starting *Author to whom correspondence should be addressed at: Unitat de Alcohologia de la Generalitat de Catalunya,Villaroel, , Barcelona, Spain. Tel.: ; Fax: ; tgual@ clinic.ub.es drinking. Alternatively, depression may precede and trigger excessive alcohol consumption as an automedication response. These pathways to comorbidity are not mutually exclusive, and patient subgroups with different aetiologies may exist. For example, Schuckit (1983) postulated 20 years ago that patients could be divided into two groups, primary alcoholics with secondary depression, and symptomatic alcoholics with premorbid depression. The latter may correspond to the Type III alcoholics with chronic mood disorders described by Lesch (Lesch et al., 1988). The different hypotheses do, however, make a testable prediction, namely that if depression is secondary to alcohol dependence, it should resolve with abstinence, whereas if alcohol dependence is secondary to depression, or if the two are independent, then it should not resolve. Numerous studies (e.g. Brown and Schuckit, 1988; Brown et al., 1995; Kiefer and Barocka, 1999) have reported that depressive symptoms do indeed abate spontaneously within a month of detoxification in alcoholdependent patients without premorbid depression, whilst they do not in those with symptomatic alcoholism. On the other hand, in patients with pre-existing depression, drinking behaviour may improve following successful treatment of depressive symptoms. If depressive symptoms resolve spontaneously with abstinence, it may not be necessary specifically to treat depression once detoxification has been successfully completed, at least in primary alcoholism (Schuckit, 1985, 1994; Anthenelli and Schuckit, 1993). Treatment remains necessary in patients with symptomatic alcoholism. However, even in patients with primary alcoholism, antidepressant treatment may be useful in order to hasten the rate of recovery and thus decrease the risk of relapse or suicide. In addition, given the proposed role of serotonergic dysfunction in both depression and alcohol dependence (Heinz et al., 2001), antidepressants acting on this transmitter system may have additional beneficial effects on drinking behaviour. Data 619 Alcohol & Alcoholism 38 Medical Council on Alcohol 2003; all rights reserved
2 620 A. GUAL et al. showing that selective serotonin reuptake inhibitors (SSRI) consistently reduce alcohol consumption in experimental animals and from healthy human volunteers, have supported this notion (Sellers et al., 1991; Naranjo and Knoke, 2001). There have been a number of clinical trials of antidepressants in alcohol dependence in patients with or without depressive symptoms, whose results have conflicted (Kranzler 2000; Thase et al., 2001). Most data suggest that SSRI and tricyclic antidepressants have limited, if any, efficacy on reducing consumption in non-depressed subjects, whereas in patients with pre-existing depression (symptomatic alcoholism) both depressive symptoms and drinking behaviour improved. However, differences in the study populations included, and in the methodology used, make comparisons and conclusions difficult. The most extensive data concern the use of fluoxetine and citalopram. Four studies have evaluated the use of sertraline in depressed alcohol-dependent patients. A small first open-label uncontrolled study in 17 recently detoxified alcohol-dependent patients showed improvement of depressive symptoms (Roy, 1996b). This stimulated a double blind, placebo-controlled trial in the same centre (Roy, 1998), which demonstrated a more rapid resolution of depressive symptoms in patients treated with sertraline compared to placebo. All the patients were abstinent throughout the study. This was followed by a larger clinical trial in 100 patients, stratified according to the presence or absence of lifetime depression (Pettinati et al., 2001). In this study, depressive symptoms improved in both treatment groups of depressed patients, with no difference between groups. Patients were stratified according to lifetime incidence of depression. Drinking outcome was superior in the sertraline treatment set for patients without a history of depression, but not for patients with current or previous depression. In the fourth study, which was also randomized and placebocontrolled, 59 non-depressed, recently-detoxified alcoholdependent patients were treated either with sertraline or with placebo for 6 months (Coşkunol et al., 2002). A small and transient difference in abstinence rates between treatment groups in favour of sertraline was observed. In light of the somewhat contradictory findings previously obtained, we have carried out a further double-blind, placebocontrolled randomized trial of sertraline in recently detoxified patients with current depressive symptoms. This study had two primary objectives: (1) to evaluate the efficacy of sertraline at achieving stable abstinence in recently detoxified alcohol-dependent patients with major depression or dysthymia, and (2) to evaluate the efficacy of this drug at ameliorating depressive symptoms and quality of life in these patients. A secondary objective was to evaluate the tolerability and safety of sertraline in such patients. Because patient heterogeneity may have contributed to the variability in the results of previous studies of SSRI in alcohol-dependent patients, strict entry criteria were imposed in order to increase the chances of obtaining an unambiguous result. PATIENTS AND METHODS The study was a double-blind, placebo-controlled, parallel group randomized clinical trial, performed in a single centre, the Alcohol Unit of the Hospital Clínico y Provincial in Barcelona. The inclusion period lasted from February 1998 to January 2001, and the treatment period for 24 weeks following inclusion. Patients Patients were recruited into the study from those outpatients attending the Alcohol Unit therapeutic programme, and having recently undergone an acute alcohol detoxification. In order to enter the study, patients were required to be at least 18 years old, to fulfil DSM-IV (American Psychiatric Association, 1994) and ICD-10 (World Health Organisation, 1992) diagnostic criteria for alcohol dependence and for major depression or dysthymia or both, and to have remained abstinent for at least 2 weeks following detoxification. In addition, patients had to have a negative drug and alcohol urine screen at inclusion. Female patients of child-bearing age had to have a negative pregnancy test at inclusion, and were required to use an effective and safe contraceptive method for the 3 months preceding the study, and throughout the study duration. Written informed consent was required from all patients. The following patients were excluded from the study. (1) Women who were pregnant, breast-feeding or who were of childbearing potential and were not using reliable contraceptive methods or who wished to become pregnant during the study or within a month after the study. (2) Patients with a primary psychiatric disorder apart from alcohol dependence and depressive symptoms. (3) Patients with moderate or severe liver disease including active cirrhosis or acute hepatitis. (4) Patients showing a high suicide risk. (5) Patients whom the investigator considered would require therapy with additional psychotropic drugs, electroconvulsive therapy (ECT) or intensive psychotherapy during the study. (6) Patients with a history of convulsive disorders, cerebral organic disease or laxative misuse within the 6 months prior to receiving the test drug. (7) Patients who had received therapy with depot neuroleptics during the 6 months prior to their inclusion in the study. (8) Patients requiring therapy with reserpine, methyldopa, guanetidine or clonidine, or who might require general anaesthesia or drugs that interact with sertraline or any serotonergic drug during the study. (9) Patients with a history of failure on sertraline or any other serotonin reuptake selective inhibitor, either alone or combined with another therapy, for treating the current depressive episode. (10) Patients in whom sertraline therapy was contraindicated. (11) Patients with the following diseases: severe allergies or multiple adverse reactions to drugs, unstable thyroid disease, severe organic diseases, or patients who had suffered severe infections or major surgery one month before their inclusion in the study. (12) Patients considered being insufficiently motivated for the therapy or with other emotional or intellectual problems that might limit the patient s ability to comply with the protocol requirements. (13) Patients who had been involved in other clinical studies within the 6 months prior to the onset of this study or who were involved in such studies simultaneously with this study. (14) Patients who had not undergone a sufficient wash-out period since the administration of previous psychotropic medication. (15) Patients who insisted on giving blood while participating in the study and/or a month after the
3 SERTRALINE IN ALCOHOL DEPENDENCE 621 end of the study. (16) Patients with a prothrombin time out of normal range. Patients fulfilling the entry criteria were then randomized to receive either placebo or sertraline ( mg/day) for the following 24 weeks. The investigator did not have access to the randomization code. The sertraline dose was initially 50 mg/day and could be titrated up to 150 mg/day over the first 8 weeks at the investigator s discretion. Matching packets containing placebo were provided for all possible sertraline dose progressions, so that titration could be performed doubleblind. Patients were issued with diary cards on which to record alcohol consumption on a daily basis. Study visits were programmed at 2, 4, 8, 12, 18 and 24 (study-end) weeks following inclusion, during which data on alcohol consumption, depressive symptoms and general clinical wellbeing were recorded. Outcome measures The efficacy variables assessed included measures of alcohol consumption, depressive symptoms and quality of life. The primary efficacy parameter for alcohol consumption was the rate of relapse, defined as the intake of an average of 50 g alcohol per day for at least 3 days per week or the single intake of 100 g alcohol in a single dose. Secondary efficacy outcomes for alcohol consumption included the rate of treatment failure (defined as the occurrence of at least three relapses as defined above during the course of the study), cumulative abstinence duration (defined as the number of days of abstinence recorded during the study) and the time to first relapse. Depressive symptoms were assessed using the Montgomery and Åsberg Depression Rating Scale (MADRS; Montgomery and Åsberg, 1979), administered at baseline and at follow-up visits at weeks 2, 4, 8, 12, 18 and 24, and the 17-item Hamilton Depression Rating Scale (HAM-D; Hamilton, 1967), administered at baseline and at study end (week 24). The primary efficacy parameter was the responder rate, responders being defined as those patients having a reduction of at least 50% with respect to baseline in scores on the MADRS. Secondary efficacy measures were changes in overall MADRS and HAM-D scores during the study. Quality of life was assessed using the Spanish version of the SF-36 health-related quality of life questionnaire at inclusion and study end (Ware and Sherbourne, 1992; Alonso et al., 1995). Each of the eight items of the scale (PF, physical functioning; RP, role limitation due to physical problems; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role limitation due to emotional problems; MH, mental health), as well as the composite physical (PCS) and mental (MCS) summary scores were determined. Assessment was based on change and percentage of change from baseline to last visit in components summary. Safety assessments Adverse events, spontaneously reported by the patient or observed by the investigator, were recorded at each study visit, and vital signs measured. Each treatment emergent adverse event was rated for severity and potential implication to the study treatment, and classified according to the WHO ART system. Blood samples were taken at inclusion, day 30 and at study end, and standard laboratory tests performed. Statistical analyses The study population analysed for efficacy was an intention to treat population, defined as all randomized patients having taken study medication at least once and having providing baseline data on primary outcome measures. Safety data was assessed for all patients having taken study medication. For alcohol consumption data, patients with missing assessments at last observation were treated as non-abstinent. For depression scale scores, missing data were handled on the principle of Last Observation Carried Forward. Categorical variables were compared with chi-squared ( 2 ) test or Fisher s exact test as appropriate. Changes in rating scores over the study period were compared by an analysis of covariance (ANCOVA), and time to endpoint variables by Kaplan Meier survival analysis. Two-tailed comparisons were made throughout and a P-value of 0.05 was considered significant. All data were controlled and analysed centrally using the SAS Version 8.2 software package. The sample size for the study was determined by a priori power calculations, based in previous clinical trials of acamprosate in alcohol dependence with a similar design, assuming an risk of 0.05, a risk of 0.20, a power of 80% and an anticipated inter-group difference of at least 20% in cumulative abstinence duration proportion. These provided an anticipated sample size of 50 patients per group. Ethics The study was conducted in accordance with the Declaration of Helsinki (Hong Kong Amendment), Good Clinical Practice (European Guidelines) and pertinent Spanish and Catalan legal and regulatory requirements. Written informed consent was obtained from each subject. The protocol was submitted to, and approved by, the Ethics Committee of the Hospital Clinic of Barcelona. RESULTS Patient disposition Overall, 88 patients were screened for inclusion in the study, and 83 were actually randomized. These constituted the Intent to Treat population for which the efficacy data was analysed (Table 1). Thirty-seven patients withdrew prematurely from the study. The principal reasons for this were loss to follow-up (11 patients), protocol violations (nine patients) and adverse events (six patients). No other motive concerned more than five patients. Overall, 46 patients completed the protocol as planned (55%). There were no differences in rates of premature study discontinuation or in Table 1. Patient disposition in a study on sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder in a randomized controlled trial in Spain Placebo Sertraline Patients randomized (n 83) Withdrawn prior to end of treatment 17 (43.6%) 20 (45.4%) Completed treatment 22 (56.4%) 24 (54.6%) Data are presented as number of patients (%) for the intent to treat population.
4 622 A. GUAL et al. protocol violations between the two treatment sets. The mean ( SD) time on study medication was days in the placebo group and days in the sertraline group. Patient characteristics The demographic and clinical characteristics of the patients at baseline are presented in Table 2. The two groups were comparable with all parameters evaluated. The demographic features of the group were typical of alcohol-dependent patients on detoxification programmes, with a mean age of 47 years, and a male predominance. Drinking history was similar between both groups, with an average dependency duration of around 16 years. Eighty-one patients fulfilled diagnostic criteria for major depression and the remaining two criteria for dysthymia. The mean baseline scores on both depression rating scales were intermediate, consistent with mild to moderate depression. Only 28 patients (34%) had MADRS scores at inclusion of 26, consistent with severe depression. The quality of life scores were low compared to normative data on both the physical and mental component subscales. Drinking behaviour Over the 6-month study period, nine patients in the placebo group (23.1%) and 14 in the sertraline group (31.8%) relapsed (Table 3). When relapse did occur, this tended to be late in the study (median time to relapse 150 days). Similar good treatment outcomes were observed on the other drinking outcome measures (Table 3). The cumulative abstinence duration corresponded to over 80% of the total study duration in both treatment groups. There were no differences between treatment groups for any of the drinking outcome measures. Depressive syndromes In terms of treatment response ( 50% improvement in the MADRS score), 39% of patients in the placebo group and 44% of patients in the sertraline group responded over the study period. There was a significant amelioration of depressive symptoms in both treatment groups as determined by scores on the MADRS and HAM-D scales (Fig. 1). Thirtyseven of the 61 patients evaluable at the last programmed study visit (24 weeks) were considered to be in remission (HAM-D score 7 at study end). There was a marginally better outcome in the sertraline group on all measures, but this was not statistically significant. To specify any potential benefit attributable to sertraline, two subgroups of patients were analysed, corresponding to MADRS scores at inclusion above (severe depression) and below (mild to moderate depression) 26. In the former subgroup, greater overall improvement and a greater proportion of patients in remission were observed in patients receiving sertraline than in those receiving placebo (Fig. 2). On the other hand, no difference in outcome was observed in the patients with MADRS scores 26. Quality of life Concerning the quality of life data, all items of the SF-36 scale improved over the length of the study period in both of the treatment and the placebo groups (Fig. 3). In general, greater improvement was observed for mental health items than for physical health items. On the mental health item, the sertraline group improved more than the placebo group. Safety assessment The most frequently reported adverse events were headache, flu-like symptoms and dizziness (Table 4). No difference between the two treatment groups was observed in the incidence of any of these adverse events. The incidence of gastrointestinal adverse events was low ( 10% of patients). DISCUSSION Concerning drinking outcome, the principal finding of this study was the very good outcome of all patients, regardless of treatment group. Of the 83 patients included, 60 (72%) remained abstinent throughout the 6-month study period. This Table 2. Demographic and clinical characteristics of patients at baseline in a study on sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder in a randomized controlled trial in Spain Parameter Placebo (n 39) Sertraline (n 44) Sex Male (%) Female (%) 21 (53.9%) 18 (46.1%) 23 (52.3%) 21 (47.7%) Age (years) Mean [ SD] Median [Range] 47.3 [9.9] 46.9 [ ] 46.1 [9.2] 44.4 [ ] Duration of Alcoholism (years) Mean [ SD] Median [Range] 18.7 [9.4] 14.5 [ ] 13.7 [8.2] 15.0 [ ] Duration of Depression (years) Mean [ SD] Median [Range] 3.3 [5.0] 1.0 [ ] 3.3 [4.73] 0.9 [ ] MADRS Score Mean [ SD] Median [Range] 22.4 [8.0] 21 [5 43] 22.7 [6.9] 21 [10 36] HAM-D Scale Score Mean [ SD] Median [Range] 12.8 [4.0] 14 [5 20] 13.9 [5.6] 14 [3 30] SF36 Physical Component Score Mean [ SD] Median [Range] 47.0 [11.0] 49.9 [ ] 48.6 [9.6] 49.0 [ ] SF36 Mental Component Score Mean [ SD] Median [Range] 41.9 [10.1] 43.4 [ ] 36.9 [13.1] 38.5 [ ] Table 3. Efficacy outcome measures: drinking behaviour in a study on sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder in a randomized controlled trial in Spain Parameter Placebo (n 39) Sertraline (n 44) P Relapse rate n (%) 9 (23.1) 14 (31.8) 0.37 Mean time to relapse (days) (mean SD) Mean cumulative abstinence duration (days) (mean SD) Cumulative abstinence duration (%)
5 SERTRALINE IN ALCOHOL DEPENDENCE 623 Fig. 1. Evolution of depression rating scales over the study period in a study on sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder in a randomized controlled trial in Spain. Scores on the Montgomery and Åsberg Depression Rating Scale (MADRS; left panel) and Hamilton Depression Rating Scale (HAM-D; right panel) at inclusion (open columns and at study end (filled columns). Fig. 2. Depression outcome according to severity at baseline in a study on sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder in a randomized controlled trial in Spain. Patients were divided into two sub-groups according to MADRS scores at inclusion, of 26 or 26. Data are presented for improvement (% change in MADRS score between inclusion and study end), response rates (patients showing 50% of improvement in the MADRS score) and remission rates (patients with MADRS score 7 at study end). Open columns: placebo group; filled columns: sertraline group. somewhat surprising result can be compared with a previous randomized clinical trial performed in our centre with acamprosate (Gual and Lehert, 2001), using a very similar design, where the overall rate of complete abstinence was 40%. Similarly, for the cumulative abstinence duration proportion, we obtained a value of 0.85, compared to 0.52 (acamprosate) and 0.41 (placebo) in the previous study. However, it should be noted that the criterion of abstinence was less severe in the current study (consumption of more than 50 g of alcohol) than in the acamprosate study (any alcohol consumption at all). Fig. 3. Evolution of scores on SF-36 scale during a study on sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder in a randomized controlled trial in Spain. The data represent the difference in score on each item and the two component scores between baseline and the last study visit (24 weeks). Open columns: placebo group; filled columns: sertraline group. PF, physical functioning; RP, role limitation due to physical problems; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role limitation due to emotional problems; MH, mental health; PCS, physical component summary score; MCS, mental component summary score. NS, not significant; P-values were determined using a rank analysis of covariance. We suggest that the excellent abstinence rates observed in this study may be due to the rigorous entry criteria used. Many patients with characteristics known to be determinants of poor outcome were excluded from the protocol (e.g. patients with associated substance abuse, poor motivation or other psychiatric problems). In fact, the included patients represent only a very small proportion of all the patients attending the clinic during the inclusion period who were screened for compatibility with the entry criteria (83 of 1758). The patients included may thus represent a sample with an intrinsically good prognosis. Given the high rates of abstinence in the placebo group, it was not possible to determine any extra benefit in those patients treated with sertraline. To address this question, a study could be performed in alcohol-dependent patients who are more representative of those in alcohol clinic consultation, such as those included in our acamprosate study. No particular tolerability problems in these alcoholdependent patients treated with sertraline were revealed in this study. In particular, there was no difference in the incidence of gastrointestinal side-effects between the two treatment groups. This is important for treatments for alcohol-dependent patients who often have impaired gastrointestinal or hepatic function. Concerning depression, again a high degree of overall improvement was observed, and the final mean Hamilton Depression Rating Score at the end of the study was below the diagnostic threshold for syndromal depression. A similar level of response was observed in both treatment groups, consistent with the idea that depressive symptoms generally improve when patients stop drinking. The high rates of absolute abstinence found in the study may explain the good outcome on depressive symptoms. Our patients would thus correspond to patients with primary alcohol dependence and symptomatic (secondary) depression as defined by Schuckit (1985).
6 624 A. GUAL et al. Table 4. Adverse events reported during a study on sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder in a randomized controlled trial in Spain Placebo (n 39) Sertraline (n 44) Global (n 83) Adverse event n % n % n % Headache 11 (28.2) 12 (27.3) 23 (27.7) Influenza-like symptoms 6 (15.4) 6 (13.6) 12 (14.5) Dizziness 5 (12.8) 5 (11.4) 10 (12.0) Dyspepsia 2 (5.1) 6 (13.6) 8 (9.6) Diarrhoea 3 (7.7) 4 (9.1) 7 (8.4) Nausea 3 (7.7) 4 (9.1) 7 (8.4) Procedure (medical/surgical/health service) 2 (5.1) 5 (11.4) 7 (8.4) Paresthesia 4 (10.3) 1 (2.3) 5 (6.0) Back pain 2 (5.1) 3 (6.8) 5 (6.0) Coughing 2 (5.1) 3 (6.8) 5 (6.0) Only adverse events occurring in over 5% of patients overall are listed. Data are presented as absolute number of patients (%). The recruitment of patients in an alcohol clinic environment may favour the inclusion of such patients, compared with studies where patients are recruited in a general psychiatry department. For example, in the study by Cornelius et al. (1997), where a beneficial effect of the SSRI on drinking was reported, many of the patients were admitted because they were suicidal, rather than because they were seeking help with drinking problems. Our study does not support any particular advantage of using an antidepressant either to improve response rates or to accelerate remission in this type of patient. Nonetheless, the failure to demonstrate any added treatment benefit with sertraline may not mean that there is none. It should be noted that a significant proportion of large randomized clinical trials of SSRI in non-alcohol-dependent populations have failed to demonstrate a treatment effect, especially where there was a large placebo response. Moreover, the patients included in this study had relatively low baseline scores on depression scales at inclusion, and should be considered as suffering from mild to moderate depression. Responses to antidepressants in such alcohol-dependent patients may be less striking than in patients with more severe disease. In the study of desipramine by Mason et al. (1996), where patients were stratified according to whether they fulfilled diagnostic criteria for a major depressive episode, treatment effects on both depressive symptoms and abstinence were only observed in the major depression group. The study of fluoxetine by Cornelius et al. (1997), which of all the studies of antidepressants in alcohol dependence has demonstrated the most robust effects, included inpatients with severe depression and high suicide risk (HAM-D scores at inclusion of 33 compared with 13 in the present study). Although any interpretation should be treated with caution owing to the low patient numbers, the sub-group analysis of our study performed according to depression severity would support this notion. This showed that sertraline provided a significant benefit to patients with more severe depression and none to patients with milder depression. The current data can be compared with previous data obtained with sertraline in alcohol-dependent patients. The patients included in our study are very similar to the depression subgroup in the study by Pettinati et al. (2001), in terms of depression severity, and, as in this subgroup, we found that both drinking outcome or depressive symptoms evolved favourably following detoxification, with no difference between sertraline and placebo groups in both outcomes. In contrast, the patients included in the study by Roy et al. (1998) had more severe symptoms of depression, which persisted for at least 2 weeks before inclusion into the study, and may correspond to patients with primary depression. A treatment response to sertraline was noted in this study for depressive symptoms. Drinking outcomes were not reported. Finally, differences in the definition of abstinence confound comparison with the study reported by Coşkunol et al. (2002), although the patients included here resembled those in the non-depressed group in the study by Pettinati et al. (2001), where a favourable effect of sertraline on drinking outcome was also observed, rather than the patients in our study. In conclusion, we could not evaluate the efficacy of sertraline in improving abstinence in alcohol-dependent patients due to the extremely low relapse rates encountered in the study. Our findings on the evolution of depressive symptoms are consistent with the hypothesis of Schuckit (1983; 1985; 1994) that depression encountered in most alcohol-dependent patients is secondary to a primary alcohol dependence and will spontaneously resolve with abstinence. These patients do not benefit from sertraline treatment. On the other hand, this drug may be useful in patients with primary depression, or more severe depression, as found in the study by Roy et al. (1998). We would recommend, however, that physicians should wait 4 weeks to see whether symptoms resolve spontaneously before initiating treatment. In such cases, sertraline offers certain advantages over other antidepressants, since it is well-tolerated, has no active metabolites and little impact on hepatic enzymes and can thus be used safely in patients with potentially impaired hepatic function. REFERENCES Alonso, J., Prieto, L. and Antó, J. M. (1995) La versión española del SF-36 Health Survey (Cuestionário de Salud SF-36): un instrumento para la medida de los resultados clínicos. Medicina Clínica 104, American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn). American Psychiatric Association, Washington, DC.
7 SERTRALINE IN ALCOHOL DEPENDENCE 625 Anthenelli, R. M. and Schuckit, M. A. (1993) Affective and anxiety disorders and alcohol and drug dependence: diagnosis and treatment. Journal of Addictive Disorders 12, Berner, P., Lesch, O. M. and Walter, H. (1986) Alcohol and depression. Psychopathology 19 Suppl. 20, Brown, S. A. and Schuckit, M. A. (1988) Changes in depression among abstinent alcoholics. Journal of Studies on Alcohol 49, Brown, S. A., Inaba, R. K., Gillin, J. C., Schuckit, M. A., Stewart, M. A. and Irwin, M. R. (1995) Alcoholism and affective disorder: clinical course of depressive symptoms. American Journal of Psychiatry 152, Cornelius, J. R., Salloum, I. M., Ehler, J. G., Jarrett, P. J., Cornelius, M. D., Perel, J. M., Thase, M. E. and Black, A. (1997) Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. Archives of General Psychiatry 54, Coşkunol, H., Gökden, O., Sabri Ercan, E., Bayraktar, E., Tuǧlular, I. and Saygili, R. (2002) Long-term efficacy of sertraline in the prevention of relapses in alcohol-dependent patients: a single-center, double-blind, randomised, placebo-controlled, parallel-group study. Current Therapeutic Research 63, Driessen, M., Meier, S., Wetterling, T., Lange, W. and Junghanns, K. (2001) The course of anxiety, depression and drinking behaviours after completed detoxification in alcoholics with and without comorbid anxiety and depressive disorders. Alcohol and Alcoholism 36, Gual, A. and Lehert, P. (2001) Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol and Alcoholism 36, Hamilton, M. (1967) Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 6, Heinz, A., Mann, K., Weinberger, D. R. and Goldman, D. (2001) Serotonergic dysfunction, negative mood states, and response to alcohol. Alcoholism: Clinical and Experimental Research 25, Kendler, K. S., Davis, C. G. and Kessler, R. C. (1997) The familial aggregation of common psychiatric and substance use disorders in the National Comorbidity Survey: a family history study. British Journal of Psychiatry 170, Kessler, R. C., McGonagle, K. A., Zhao, S., Nelson, C. B., Hughes, M., Eshleman, S., Wittchen, H. U. and Kendler, K. S. (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry 51, Kiefer, F. and Barocka, A. (1999) Secondary depression in weaned alcoholics: implications of Lesch s typology of chronic alcoholism. Alcohol and Alcoholism 34, Kranzler, H. R. (2000) Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research. Alcohol and Alcoholism 35, Lesch, O. M., Dietzel, M., Musalek, M., Walter, H. and Zeiler, K. (1988) The course of alcoholism. Long-term prognosis in different types. Forensic Science International 36, Mason, B. J., Kocsis, J. H., Ritvo, E. C. and Cutler, R. B. (1996) A doubleblind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. Journal of the American Medical Association 275, Montgomery, S. A. and Åsberg, M. (1979) A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, Mueller, T. I., Lavori, P. W., Keller, M. B., Swartz, A., Warshaw, M. W., Hasin, D., Corvell, W., Endicott, J., Rice, J. and Akiskal, H. (1994) Prognostic effect of the variable course of alcoholism on the 10-year course of depression. American Journal of Psychiatry 151, Murphy, G. E., Wetzel, R. D., Robins, E. and McEvoy, L. (1992) Multiple risk factors predict suicide in alcoholism. Archives of General Psychiatry 49, Naranjo, C. A. and Knoke, D. M. (2001) The role of selective serotonin reuptake inhibitors in reducing alcohol consumption. Journal of Clinical Psychiatry 62 Suppl. 20, O Sullivan, K. (1984) Depression and its treatment in alcoholics: a review. Canadian Journal of Psychiatry 29, O Sullivan, K., Rynne, C., Miller, J., O Sullivan, S., Fitzpatrick, V., Hux, M., Cooney, J. and Clare, A. (1988) A follow-up study on alcoholics with and without co-existing affective disorder. British Journal of Psychiatry 152, Pettinati, H. M., Volpicelli, J. R., Luck, G., Kranzler, H. R., Rukstalis, M. R. and Cnaan, A. (2001) Double-blind clinical trial of sertraline treatment for alcohol dependence. Journal of Clinical Psychopharmacology 21, Regier, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L. and Goodwin, F. K. (1990) Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. Journal of the American Medical Association 264, Rounsaville, B. J., Dolinsky, Z. S., Babor, T. F. and Meyer, R. E. (1987) Psychopathology as a predictor of treatment outcome in alcoholics. Archives of General Psychiatry 44, Roy, A. (1996a) Aetiology of secondary depression in male alcoholics. British Journal of Psychiatry 169, Roy, A. (1996b) Treating depression among alcoholics. Canadian Journal of Psychiatry 41, Roy, A. (1998) Placebo-controlled study of sertraline in depressed recently abstinent alcoholics. Biological Psychiatry 44, Schuckit, M. (1983) Alcoholic patients with secondary depression. American Journal of Psychiatry 140, Schuckit, M. A. (1985) The clinical implications of primary diagnostic groups among alcoholics. Archives of General Psychiatry 42, Schuckit, M. A. (1994) Alcohol and depression: a clinical perspective. Acta Psychiatrica Scandinavica Suppl 377, Sellers, E. M., Higgins, G. A., Tomkins, D. M., Romach, M. K. and Toneatto, T. (1991) Opportunities for treatment of psychoactive substance use disorders with serotonergic medications. Journal of Clinical Psychiatry 52 Suppl., Swendsen, J. D. and Merikangas, K. R. (2000) The comorbidity of depression and substance use disorders. Clinical Psychology Review 20, Thase, M. E., Salloum, I. M. and Cornelius, J. D. (2001) Comorbid alcoholism and depression: treatment issues. Journal of Clinical Psychiatry 62 Suppl. 20, Ware, J. E. and Sherbourne, C. D. (1992) The MOS 36-item Short Form Health Survey I: conceptual framework and item selection. Medical Care 30, World Health Organisation (1992) ICD-10 International Statistical Classification of Diseases and Related Health Problems, 10th Revision. WHO, Geneva.
Summary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationTrial No.: RIS-USA-102 Clinical phase: III
SYNOPSIS Trial identification and protocol summary Company: Johnson & Johnson Pharmaceutical Research and Development, a division of Janssen Pharmaceutica, N.V. Finished product: Risperdal Active ingredient:
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More informationALCOHOL DEPENDENCE SYNDROME AND OTHER PSYCHIATRIC ILLNESSESS
Research article ALCOHOL DEPENDENCE SYNDROME AND OTHER PSYCHIATRIC ILLNESSESS Dr. Amitabh Saha Dept of Psychiatry, Command Hospital Pune -411040 India E-mail: sahaing@gmail.com Abstract Alcohol is the
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBRL /RSD-101C0D/1/CPMS-704. Report Synopsis
Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with
More informationAntidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder
updated 2012 Antidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder Q10: Are antidepressants (Tricyclic antidepressants
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 1 October 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 1 October 2008 EFFEXOR SR 37.5 mg prolonged-release capsule B/30 (CIP: 346 563-3) EFFEXOR SR 75 mg prolonged-release
More informationA Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression
REVIEW ARTICLE Drug Saf 2011; 34 (9): 709-731 0114-5916/11/0009-0709/$49.95/0 ª 2011 Adis Data Information BV. All rights reserved. A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression
More informationComorbidity With Substance Abuse P a g e 1
Comorbidity With Substance Abuse P a g e 1 Comorbidity With Substance Abuse Introduction This interesting session provided an overview of recent findings in the diagnosis and treatment of several psychiatric
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationStudy Center(s): The study was conducted at 39 study sites in Japan.
SYNOPSIS Issue Date: 20 NOVEMBER 2012 Name of Sponsor/Company Janssen Pharmaceutical K. K. Name of Finished Product CONCERTA Name of Active Ingredient(s) Methylphenidate HCl Protocol No.: JNS001-JPN-A01
More informationPharmacotherapy for Alcohol Dependence
Evidence Report/Technology Assessment: Number 3 Pharmacotherapy for Alcohol Dependence Summary Under its Evidence-Based Practice Program, the Agency for Health Care Policy and Research (AHCPR) is developing
More informationSuitable dose and duration of fluvoxamine administration to treat depression
PCN Psychiatric and Clinical Neurosciences 1323-13162003 Blackwell Science Pty Ltd 572April 2003 1098 Dose and duration of fluvoxamine S. Morishita and S. Arita 10.1046/j.1323-1316.2002.01098.x Original
More informationStudie 083 (950E-CNS )
Studie 083 (950E-CNS-0005-083) Studienberichtssynopse Clinical Study Report 950E-CNS-0005-083 EFFECTS OF THE USE OF REBOXETINE AS A SUBSTITUTE FOR SELECTIVE SEROTONIN REUPTAKE INHIBITOR ANTIDEPRESSANTS
More informationSuicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative
Suicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative Robert I. Simon, M.D.* Suicide risk is increased in patients with Major Depressive Disorder with Melancholic
More informationComorbidity of Depression and Other Diseases
Comorbidity of Depression and Other Diseases JMAJ 44(5): 225 229, 2001 Masaru MIMURA Associate Professor, Department of Psychiatry, Showa University, School of Medicine Abstract: This paper outlines the
More informationWith a lifetime prevalence of 30%, alcohol use disorders
Evidence is mixed for antidepressants, alcohol dependence medications, or a combination Mayumi Okada Gianoli, PhD Postdoctoral Fellow Department of Psychiatry Yale University School of Medicine Ismene
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information11. Psychopharmacological Intervention
11. Psychopharmacological Intervention 11.1 Goals of Psychopharmacology The goal of psychopharmacology is to ensure that patients with more severe forms of depression and those who fail to benefit adequately
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 February 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 February 2009 ABILIFY 5 mg tablets, pack of 28 (CIP: 364 069-7) ABILIFY 10 mg tablets, pack of 28 (CIP: 364 073-4)
More information2. SYNOPSIS Name of Sponsor/Company:
in patients with refractory partial seizures 14 Jun 2007 2. SYNOPSIS TITLE OF STUDY: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomized,
More informationORIGINAL ARTICLE. Major Depression in 6050 Former Drinkers. epidemiologic surveys 1-6 and reviews of the
Major Depression in 6050 Former Drinkers Association With Past Alcohol Dependence Deborah S. Hasin, PhD; Bridget F. Grant, PhD ORIGINAL ARTICLE Background: The association between alcoholism and major
More informationSupplementary Online Content
Supplementary Online Content Lam RW, Levitt AJ, Levitan RD, et al. Efficacy of bright light treatment, fluoxetine, and the combination in patients with nonseasonal major depressive disorder: a randomized
More information1 1 Evidence-based pharmacotherapy of major depressive disorder. Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A.
1 1 Evidence-based pharmacotherapy of major depressive disorder Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A. Nierenberg Massachusetts General Hospital and Harvard University, Boston,
More informationPregabalin As A Treatment for Generalized Anxiety Disorder. Ashley Storrs PGY III December 2, 2010
Pregabalin As A Treatment for Generalized Anxiety Disorder Ashley Storrs PGY III December 2, 2010 Background Information Approximately 18.1 percent of American adults 18 years or older have an anxiety
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYCL
CT Registry ID#8226 Page 1 Summary ID# 8226. Clinical Study Summary: Study B4Z-MC-LYCL Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine
More informationBRIEF REPORT FACTORS ASSOCIATED WITH UNTREATED REMISSIONS FROM ALCOHOL ABUSE OR DEPENDENCE
Pergamon Addictive Behaviors, Vol. 25, No. 2, pp. 317 321, 2000 Copyright 2000 Elsevier Science Ltd. Printed in the USA. All rights reserved 0306-4603/00/$ see front matter PII S0306-4603(98)00130-0 BRIEF
More informationDepression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol
Lindsay French PGY3 Depression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol dependence have complicated course of
More informationSupplementary Online Content
Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia
More informationAre Anti depressants Effective in the Treatment of Depressed Patients Who Do Not Seek Psychotherapy?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2012 Are Anti depressants Effective in the
More informationEMERGENCY ROOM AND PRIMARY CARE SERVICES UTILIZATION AND ASSOCIATED ALCOHOL AND DRUG USE IN THE UNITED STATES GENERAL POPULATION
Alcohol & Alcoholism Vol. 34, No. 4, pp. 581 589, 1999 EMERGENCY ROOM AND PRIMARY CARE SERVICES UTILIZATION AND ASSOCIATED ALCOHOL AND DRUG USE IN THE UNITED STATES GENERAL POPULATION CHERYL J. CHERPITEL
More informationSupplementary Material
Supplementary Material Supplementary Table 1. Symptoms assessed, number of items assessed, scoring, and cut-off points for the psychiatric rating scales: Montgomery Åsberg Depression Rating Scale, Hamilton
More informationLong term pharmacotherapy for Alcohol Dependence: Anti Craving agents
Long term pharmacotherapy for Alcohol Dependence: Anti Craving agents Myth or Reality? Complete Recovery means a medication-free state True or False? Treatment of Alcoholism Assessment Motivation Alcohol
More informationEscitalopram (S-Enantiomer of Citalopram): Clinical Efficacy and Onset of Action Predicted from a Rat Model
C Pharmacology & Toxicology 2001, 88, 282 286. Printed in Denmark. All rights reserved Copyright C ISSN 0901-9928 Escitalopram (S-Enantiomer of Citalopram): Clinical Efficacy and Onset of Action Predicted
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME /GENERIC DRUG NAME: Effexor XR /
More information1. Introduction Overview Organization of Executive Summary
Executive Summary and Discussion of the Vagus Nerve Stimulation (VNS) Therapy Depression Indication Clinical Data (Updated to Include Information from Deficiency Letter Response) Prepared By: Richard L.
More informationSupplementary Online Content
Supplementary Online Content Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized
More informationBRL /RSD-101RLL/1/CPMS-716. Report Synopsis
Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Advil / Ibuprofen
More informationSCIENTIFIC CONCLUSIONS AND GROUNDS FOR POSITIVE OPINION AND AMENDMENT OF THE LABELLING AND PACKAGE LEAFLET PRESENTED BY THE EUROPEAN MEDICINES AGENCY
ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR POSITIVE OPINION AND AMENDMENT OF THE LABELLING AND PACKAGE LEAFLET PRESENTED BY THE EUROPEAN MEDICINES AGENCY 14 Scientific conclusions Overall summary
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationDepression: selective serotonin reuptake inhibitors
Depression: selective serotonin reuptake inhibitors Selective serotonin reuptake inhibitors (SSRIs) are considered first-line treatment for the majority of patients with depression. citalopram and fluoxetine
More informationThe Pharmacological Management of Bipolar Disorder: An Update
Psychobiology Research Group The Pharmacological Management of Bipolar Disorder: An Update R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon.
More informationReviews/Evaluations. Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients. Pharmacotherapeutic Options
Reviews/Evaluations Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients Childhood major depressive disorder (MDD) has become recognized as a serious and common illness affecting between
More informationSummary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ
CT Registry ID#236 Page 1 Summary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ Title of Study: Fluoxetine: Fluoxetine versus Placebo in Adolescent Depressed Patients Investigator(s): This single-center
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationApplication of Psychotropic Drugs in Primary Care
Psychotropic Drugs Application of Psychotropic Drugs in Primary Care JMAJ 47(6): 253 258, 2004 Naoshi HORIKAWA Professor, Department of Psychiatry, Tokyo Women s Medical University Abstract: The incidence
More informationSponsor. Generic drug name. Trial indication(s) Protocol number. Protocol title. Phase of Drug Development. Study Start/End Dates
Sponsor Novartis Generic drug name SAB378 [Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone] Trial indication(s) Postherpetic neuralgia (PHN) Protocol number CSAB378A2201 Protocol title A multicenter,
More informationSetting The setting was primary and secondary care. The economic evaluation was conducted in France.
Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France Brown M C, van Loon J M, Guest J F Record Status This is a critical abstract of an
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSetting Non-profit psychiatric hospital. The economic analysis was carried out in the USA.
Inpatient alcohol treatment in a private healthcare setting: which patients benefit and at what cost? Pettinati H M, Meyers K, Evans B D, Ruetsch C R, Kaplan F N, Jensen J M, Hadley T R Record Status This
More informationVO- PMHP Treatment Guideline 102: Electroconvulsive Therapy (ECT)
VO- PMHP Treatment Guideline 102: Electroconvulsive Therapy (ECT) Diagnostic Guidelines: Introduction: Electroconvulsive Therapy has been in continuous use for more than 60 years. The clinical literature
More informationPharmacotherapy of Alcohol Use Disorders
Pharmacotherapy of Alcohol Use Disorders Roger D. Weiss, MD Professor of Psychiatry, Harvard Medical School Chief, Division of Alcohol and Drug Abuse McLean Hospital rweiss@mclean.harvard.edu Consultant
More informationR (paliperidone palmitate) Clinical Study Report R SCA-3004
SYNOPSIS Name of Sponsor/Company Janssen Scientific Affairs, LLC Name of Finished Product INVEGA SUSTENNA Name of Active Ingredient(s) Status: Approved Date: 10 March 2014 Prepared by: Janssen Scientific
More informationJanssen-Cilag EMEA Medical Affairs a division of Janssen Pharmaceuticals N.V.
SYNOPSIS Issue Date: Final 22 July 2009 [Document No.: EDMS-PSDB-9245102] Name of Sponsor/Company Name of Finished Product Risperdal Consta Name of Active Ingredient(s) Protocol No.: RIS-BMN-3001 Janssen-Cilag
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationStatistical analysis plan - The Oslo Study of Clonidine in Elderly Patients with Delirium; LUCID
Statistical analysis plan - The Oslo Study of Clonidine in Elderly Patients with Delirium; LUCID Note: This statistical analysis plan was written prior to unblinding of randomisation / treatment allocation.
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
Public Disclosure Synopsis Protocol A7772 September 25 Final PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
More informationGuilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.
1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More informationCLINICAL INVESTIGATION OF MEDICAL PRODUCTS IN THE TREATMENT OF GENERALISED ANXIETY DISORDER, PANIC DISORDER AND OBSESSIVE- COMPULSIVE DISORDER
CLINICAL INVESTIGATION OF MEDICAL PRODUCTS IN THE TREATMENT OF GENERALISED ANXIETY DISORDER, PANIC DISORDER AND OBSESSIVE- COMPULSIVE DISORDER Guideline Title Clinical Investigation of Medical Products
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) April 2014 Review April 2017 Bulletin 197: Dapoxetine for Premature Ejaculation JPC Recommendations: To support the East of England Priorities Advisory
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 05 May 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 05 May 2010 LAMICTAL 2 mg, dispersible / chewable tablet B/30 (CIP: 354 581-7) LAMICTAL 5 mg, dispersible / chewable
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationMedicinal product no longer authorised SCIENTIFIC DISCUSSION. London, 22 November 2007 Product Name : Ariclaim Procedure No: EMEA/H/C/000552/II/0024
European Medicines Agency Post-Authorisation Evaluation of Medicines for Human Use London, 22 November 2007 Product Name : Ariclaim Procedure No: EMEA/H/C/000552/II/0024 SCIENTIFIC DISCUSSION 1/7 EMEA
More informationpaliperidone palmitate 50mg, 75mg, 100mg and 150mg prolonged release suspension for injection (Xeplion) SMC No. (713/11) Janssen-Cilag Ltd
Re-Submission paliperidone palmitate 50mg, 75mg, 100mg and 150mg prolonged release suspension for injection (Xeplion) SMC No. (713/11) Janssen-Cilag Ltd 07 October 2011 The Scottish Medicines Consortium
More informationChallenges in identifying and treating bipolar depression: a guide
Challenges in identifying and treating bipolar depression: a guide Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Overview Challenges in
More information10 INDEX Acknowledgements, i
INDEX 10 INDEX Acknowledgements, i Acute Care, Admissions to, 3.83 Discharge Planning, 3.86 Involuntary Admission Criteria, 3.84 List of Designated Provincial and Regional Mental Health Facilities, 3.83
More informationNew Research in Depression and Anxiety
New Research in Depression and Anxiety Robert Glassman Introduction Depression and anxiety are some of the most common disorders of childhood and adolescence. New research in these areas explores important
More informationSubstance use and perceived symptom improvement among patients with bipolar disorder and substance dependence
Journal of Affective Disorders 79 (2004) 279 283 Brief report Substance use and perceived symptom improvement among patients with bipolar disorder and substance dependence Roger D. Weiss a,b, *, Monika
More informationAllergan Not Applicable AGN A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose, Parallel
Peripheral Neuropathy Design, Dose Ranging Study of the Safety and Efficacy of AGN 203818 in Patients with Painful Diabetic 203818-004. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple
More information2. Chapter 2: Eligibility
2.1 Overview of Approach and Goals 2. Chapter 2: Eligibility The goal is to randomize 1375 participants over 18 years of age who meet DSM-IV criteria for alcohol dependence and are abstinent for a minimum
More informationREVIEW ARTICLE MANAGEMENT OF PATIENTS WITH MOOD DISORDERS AND COMORBID SUDS
MANAGEMENT OF PATIENTS WITH MOOD DISORDERS AND COMORBID SUDS ANNALS OF CLINICAL PSYCHIATRY 2012;24(1):38-55 REVIEW ARTICLE The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations
More informationBipolar disorder and alcoholism
Bipolar Disorder and Alcoholism Susan C. Sonne, PharmD, and Kathleen T. Brady, M.D., Ph.D. Bipolar disorder and alcoholism commonly co-occur. Multiple explanations for the relationship between these conditions
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
Study No.: 29060/717 Title: A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder Rationale: In most trials investigating
More informationThe best drug treatment for psychotic depression: antidepressants, antipsychotics or both combined?
BJPsych Advances (2017), vol. 23, 3 8 doi: 10.1192/apt.23.1.3 The best drug treatment for psychotic depression: antidepressants, antipsychotics or both combined? COMMENTARY ON COCHRANE CORNER Katharine
More informationClinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version
Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of
More informationSYNOPSIS. Study Coordinator. Study centre(s)
Drug product: Seroquel Drug substance(s): Quetiapine Document No.: 1 Edition No.: 1 Study code: D1449C00005 Date: 02 January 2007 SYNOPSIS A Randomized, Parallel Group, Open Trial Examining the Safety,
More informationClinical Perspective on Conducting TRD Studies. Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark
Clinical Perspective on Conducting TRD Studies Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark Overview of Presentation Treatment-Resistant Depression (TRD)
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationALCOHOL ABUSE AND DEPENDENCE CRITERIA AS PREDICTORS OF A CHRONIC COURSE OF ALCOHOL USE DISORDERS IN THE GENERAL POPULATION
Alcohol & Alcoholism Vol 40, No 5, pp 441 446, 2005 Advance Access publication 11 July 2005 doi:101093/alcalc/agh183 ALCOHOL ABUSE AND DEPENDENCE CRITERIA AS PREDICTORS OF A CHRONIC COURSE OF ALCOHOL USE
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationBenzodiazepine as an Adjuvant in Management of Depression
Original Article Benzodiazepine as an Adjuvant in Management of Depression Girish K and Moulya Nagraj* Department of Pharmacology, Kempe Gowda Institute of Medical Sciences, Bangalore - 560070, India ABSTRACT
More informationSYNOPSIS. Trial identification and protocol summary
SYNOPSIS Trial identification and protocol summary Company: JANSSEN PHARMACEUTICA N.V. Finished product: Risperdal Active ingredient: Risperidone (R64766) Title: The safety and efficacy of risperidone
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:
SYNOPSIS Protocol No.: TOPMAT-MIG-303 EudraCT No.: 2005-000321-29 Title of Study: A double-blind, randomised, placebo-controlled, multicentre study to investigate the efficacy and tolerability of in prolonged
More information3. Depressione unipolare
3. Depressione unipolare Depressione unipolare con mancata risposta al trattamento con SSRI Question: Should switching from SSRIs to another antidepressant class vs switching within class (SSRIs) be used
More informationStudy No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122
Page 13 of 122 3 SYNOPSIS Title of study: (International) Study No: A randomized, double-blind, parallel group, proof-of-concept study of in comparison with placebo and tolterodine in patients with symptomatic
More informationTreating alcoholrelated. depression. James Foulds Senior Lecturer National Addiction Centre Christchurch, NZ
Treating alcoholrelated depression James Foulds Senior Lecturer National Addiction Centre Christchurch, NZ Overview of talk Epidemiology and etiology of alcoholrelated comorbidity Alcohol-related depression
More informationDepressive Disorder in Children and Adolescents: Dysthymic Disorder and the Use of Self-Rating Scales in Assessment
Depressive Disorder in Children and Adolescents: Dysthymic Disorder and the Use of Self-Rating Scales in Assessment Stuart Fine, MB, FRCP (C), Marlene Moretti, MA, Glenn Haley, MA, Simon Fraser University.
More informationLondon, 07 August 2006 Product name: Keppra Procedure No. EMEA/H/C/277/II/63 SCIENTIFIC DISCUSSION
London, 07 August 2006 Product name: Keppra Procedure No. EMEA/H/C/277/II/63 SCIENTIFIC DISCUSSION 1/15 EMEA 2006 1. Introduction Epilepsy is one of the most common and challenging neurological disorders.
More informationTechnology appraisal guidance Published: 26 November 2014 nice.org.uk/guidance/ta325
Nalmefene for reducing alcohol consumption in people with alcohol dependence Technology appraisal guidance Published: 26 November 2014 nice.org.uk/guidance/ta325 NICE 2018. All rights reserved. Subject
More informationStudy No: Title: Rationale: . Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMigraine: Developing Drugs for Acute Treatment Guidance for Industry
Migraine: Developing Drugs for Acute Treatment Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2018
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More informationUPDATE April 5, 2006 BRIEFING DOCUMENT. Paroxetine Adult Suicidality Analysis: Major Depressive Disorder and Non- Major Depressive Disorder
UPDATE April 5, 2006 BRIEFING DOCUMENT Paroxetine Adult Suicidality Analysis: Major Depressive Disorder and Non- Major Depressive Disorder 1. Introduction Selective serotonin reuptake inhibitors (SSRIs)
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More information